Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial

European Journal of Cancer

Volumn 78, Issue , 2017, Pages 61-69

  Yoshino, Takayuki ^a   Obermannová, Radka ^b   Bodoky, György ^c   Garcia Carbonero, Rocio ^d   Ciuleanu, Tudor ^e   Portnoy, David C ^f   Kim, Tae Won ^g   Hsu, Yanzhi ^h   Ferry, David ^h   Nasroulah, Federico ^h   Tabernero, Josep ⁱ  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^c Szent Laszlo Hospital   (Hungary)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^g University of Ulsan College of Medicine   (South Korea)

^h ELI LILLY AND COMPANY   (United States)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Carcinoembryonic antigen; CEA; Colorectal carcinoma; Metastatic; Phase III clinical trial; Predictive; Ramucirumab

Indexed keywords

BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; RAMUCIRUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; ADULT; BLOOD; CLINICAL TRIAL; COLONIC NEOPLASMS; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RECTAL NEOPLASMS; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 85017388731     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.03.007     Document Type: Article

References (17)

1. [1] Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. 2013, International Agency for Research on Cancer, Lyon, France Available from: http://globocan.iarc.fr [Accessed 15 September 2016].
2. [2] Van Cutsem, E., Cervantes, A., Nordlinger, B., Arnold, D., Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:Suppl. 3 (2014), iii1–iii9.
3. [3] DeSantis, C.E., Lin, C.C., Mariotto, A.B., Siegel, R.L., Stein, K.D., Kramer, J.L., et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64 (2014), 252–271, 10.3322/caac.21235.
4. [4] Tabernero, J., Yoshino, T., Cohn, A.L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16 (2015), 499–508, 10.1016/S1470-2045(15)70127-0.
5. [5] Spratlin, J.L., Cohen, R.B., Eadens, M., Gore, L., Camidge, D.R., Diab, S., et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28 (2010), 780–787, 10.1200/JCO.2009.23.7537.
6. [6] Obermannová, R., Van Cutsem, E., Yoshino, T., Bodoky, G., Prausová, J., Garcia-Carbonero, R., et al. Subgroup analysis in RAISE: a randomized, double-blind phase 3 study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Ann Oncol 27 (2016), 2082–2090.
7. [7] Fakih, M.G., Padmanabhan, A., CEA monitoring in colorectal cancer. What you should know. Oncology (Williston Park, NY) 20 (2006), 579–587.
8. [8] Duffy, M.J., Lamerz, R., Haglund, C., Nicolini, A., Kalousová, M., Holubec, L., et al. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer 134 (2014), 2513–2522, 10.1002/ijc.28384.
9. [9] Prager, G.W., Braemswig, K.H., Martel, A., Unseld, M., Heinze, G., Brodowicz, T., et al. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer. Cancer Sci 105 (2014), 996–1001, 10.1111/cas.12451.
10. [10] Michl, M., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.E., et al. Baseline carcinoembryonic antigen (CEA) serum levels to predict bevacizumab-based treatment response in patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving 1st-line therapy with FOLFIRI plus cetuximab or bevacizumab (AIO KRK0306, FIRE3 trial). ASCO Annu Meet Proc, 33(15 Suppl.), 2015, 3581.
11. [11] Lazar, A.A., Cole, B.F., Bonetti, M., Gelber, R.D., Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot. J Clin Oncol 28 (2010), 4539–4544, 10.1200/JCO.2009.27.9182.
12. [12] Webb, A., Scott-Mackie, P., Cunningham, D., Norman, A., Andreyev, J., O'Brien, M., et al. The prognostic value of CEA, βHCG, AFP, CA125, CA19-9 and C-erb B-2, βHCG immunohistochemistry in advanced colorectal cancer. Ann Oncol 6 (1995), 581–588.
13. [13] Thirunavukarasu, P., Sukumar, S., Sathaiah, M., Mahan, M., Pragatheeshwar, K.D., Pingpank, J.F., et al. C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J Natl Cancer Inst 103 (2011), 689–697, 10.1093/jnci/djr078.
14. [14] Bramswig, K.H., Poettler, M., Unseld, M., Wrba, F., Uhrin, P., Zimmermann, W., et al. Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis. Cancer Res 73 (2013), 6584–6596, 10.1158/0008-5472.CAN-13-0123.
15. [15] Michl, M., Stintzing, S., von Weikersthal, L.F., Decker, T., Kiani, A., Vehling-Kaiser, U., et al. CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). Ann Oncol 27 (2016), 1565–1572, 10.1093/annonc/mdw222.
16. [16] Cho, M.T., Goldstein, L., Akiba, C., Lau, S.C., Telatar, M., Afkhami, M., et al. RAS mutational status and CEA production at initial presentation in metastatic colorectal cancer. ASCO Annu Meet Proc, 34(4 Suppl.), 2016, 542.
17. [17] Ordonez, C., Zhai, A.B., Camacho-Leal, P., Demarte, L., Fan, M.M., Stanners, C.P., GPI-anchored CEA family glycoproteins CEA and CEACAM6 mediate their biological effects through enhanced integrin alpha5beta1-fibronectin interaction. J Cell Physiol 210 (2007), 757–765.